Compare
Instil Bio, Inc. vs Protara Therapeutics, Inc. vs Neumora Therapeutics, Inc. vs Metagenomi Therapeutics, Inc.
| Latest fiscal year | Instil Bio, Inc. TIL | Protara Therapeutics, Inc. TARA | Neumora Therapeutics, Inc. NMRA | Metagenomi Therapeutics, Inc. MGX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $25.21M |
| Revenue growth (YoY) | n/a | n/a | n/a | -51.8% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | -380.9% |
| Net margin | n/a | n/a | n/a | -348.5% |
| Net income | -$71.37M | -$57.44M | -$236.93M | -$87.87M |
| EPS (Diluted) | -$10.70 | -$1.34 | -$1.45 | -$2.36 |
| Operating cash flow | -$36.62M | -$56.37M | -$206.44M | -$88.89M |
| Free cash flow | n/a | -$56.46M | n/a | -$89.47M |
| Cash & equivalents | $6.64M | $49.66M | $182.53M | $41.72M |
| Total assets | $203.52M | $209.47M | $191.05M | $221.10M |
| Total liabilities | $89.66M | $13.06M | $87.18M | $62.51M |
| Shareholders' equity | $113.87M | $196.41M | $103.87M | $158.60M |
| Return on year-end equity | -62.7% | -29.2% | -228.1% | -55.4% |
| Shares outstanding | 6.78M | 53.59M | 174.26M | 37.62M |
Revenue, most recent five fiscal years
| Fiscal year | Instil Bio, Inc. | Protara Therapeutics, Inc. | Neumora Therapeutics, Inc. | Metagenomi Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2021-12-31 | $2.95M Ended 2014-12-31 | n/a | $25.21M Ended 2025-12-31 |
| 1 year earlier | $138.0K Ended 2020-12-31 | n/a | n/a | $52.30M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $44.76M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |